ISSUES OF INDIVIDUALIZATION OF MEDICATION IN PATIENTS WITH BREAST CANCER (29-32)

Архив в PDF формате
Дата публикации статьи в журнале: 2020/02/017
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 53, Том: 1, Страницы в выпуске: 29-32
Автор: Vinnik Yu.A.
Kharkiv, Kharkiv Medical Academy of Postgraduate Education ,
Автор: Belevtsova Yu.Yu.
Kharkiv, Kharkiv Medical Academy of Postgraduate Education ,
Автор: Sadchykova M.V.
Kharkiv, Kharkiv Medical Academy of Postgraduate Education ,
Анотация: The purpose of this study was to search for approaches to individualization of adjuvant chemotherapeutic treatment of breast cancer based on a study of the effectiveness of anthracycline chemotherapy regimens in various molecular biological tumor subtypes.
Ключевые слова: breast cancer   the effectiveness of chemotherapy   molecular biological tumor subtypes  
Данные для цитирования: Vinnik Yu.A., Belevtsova Yu.Yu., Sadchykova M.V. . ISSUES OF INDIVIDUALIZATION OF MEDICATION IN PATIENTS WITH BREAST CANCER (29-32). Восточно Европейский Научный Журнал. Медицинские науки. 2020/02/017; 53(1):29-32.

Список литературы: 1. Семиглазов В.Ф., Семиглазов В.В., Палтуев Р.М. и др. Индивидуализация адъювантной терапии рака молочной железы. // Фарматека. 2011. №7. С. 8-13. 32 Wschodnioeuropejskie Czasopismo Naukowe (East European Scientific Journal) #1(53), 20 2. Carey L A., Perou C M., Livasy C A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. // JAMA. 2006. Vol. 295. P. 24492-24502. 3. Carter C L., Allen C., Henson D E. et al. Relation of Tumor Size, Lymph Node Status, and Survival in 24,740 Breast Cancer Cases. // Cancer. 1989. Vol. 63. P. 181-187. 4. Ciriello G., Sinha R., Hoadley K A. et al. The molecular diversity of Luminal A breast tumors. // Breast Cancer Res Treat. 2013. Vol. 141. P. 409–420. 5. Dawood S., Hu R., Homes M D. et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. // Breast Cancer Res Treat. 2011, Vol. 126. P. 185–192. 6. Goldhirsch A., Ingle J N., Gelber R D. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. // Ann Oncol. 2009. Vol. 20. P. 1319-29. 7. Goldhirsch A., Wood W C., Coates A S. et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early УДК 614.255.4:616.31-08-039.71 ГРНТИ 76.01.11 Breast Cancer 2011. // Ann Oncol. 2011. Vol. 22. P. 1736-47. 8. Goldhirsch A., Winer E P., Coates A S. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. // Ann Oncol. 2013. Vol. 24. P. 2206-23. 9. Haque R., Ahmed A., Inzhakova G. et al. Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades. // Cancer Epidemiol Biomarkers Prev. 2012. Vol. 21. P. 1848–1855. 10. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. // Lancet. 2012. Vol. 379. P. 432–444. 11. Lehmann B D., Pietenpol J A. Identification and use of biomarkers in treatment strategies for triplenegative breast cancer subtypes. // The Journal of Pathology. 2014. Vol. 232. P.142–150.